ATE397625T1 - Agonisten des rezeptors 3 (r3) von pituitary adenylate cyclase aktivierendem peptid (pacap) und ihre pharmakologische verwendung - Google Patents

Agonisten des rezeptors 3 (r3) von pituitary adenylate cyclase aktivierendem peptid (pacap) und ihre pharmakologische verwendung

Info

Publication number
ATE397625T1
ATE397625T1 AT00967002T AT00967002T ATE397625T1 AT E397625 T1 ATE397625 T1 AT E397625T1 AT 00967002 T AT00967002 T AT 00967002T AT 00967002 T AT00967002 T AT 00967002T AT E397625 T1 ATE397625 T1 AT E397625T1
Authority
AT
Austria
Prior art keywords
peptides
pacap
agonists
receptor
insulin
Prior art date
Application number
AT00967002T
Other languages
English (en)
Inventor
Clark Pan
Manami Tsutsumi
Armen Shanafelt
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Application granted granted Critical
Publication of ATE397625T1 publication Critical patent/ATE397625T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00967002T 1999-09-28 2000-09-27 Agonisten des rezeptors 3 (r3) von pituitary adenylate cyclase aktivierendem peptid (pacap) und ihre pharmakologische verwendung ATE397625T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40783299A 1999-09-28 1999-09-28
US59528000A 2000-06-15 2000-06-15

Publications (1)

Publication Number Publication Date
ATE397625T1 true ATE397625T1 (de) 2008-06-15

Family

ID=27020026

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00967002T ATE397625T1 (de) 1999-09-28 2000-09-27 Agonisten des rezeptors 3 (r3) von pituitary adenylate cyclase aktivierendem peptid (pacap) und ihre pharmakologische verwendung

Country Status (19)

Country Link
EP (1) EP1192182B1 (de)
AT (1) ATE397625T1 (de)
AU (1) AU7726600A (de)
CA (1) CA2379604A1 (de)
CO (1) CO5280048A1 (de)
CZ (1) CZ296858B6 (de)
DE (1) DE60039111D1 (de)
DO (1) DOP2000000071A (de)
ES (1) ES2307534T3 (de)
GT (1) GT200000162A (de)
HU (1) HUP0202175A3 (de)
MY (1) MY131983A (de)
PE (1) PE20010612A1 (de)
RU (1) RU2269354C2 (de)
SK (1) SK5552002A3 (de)
SV (1) SV2002000184A (de)
TW (1) TWI264438B (de)
UY (1) UY26360A1 (de)
WO (1) WO2001023420A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
EP1476178A4 (de) * 2002-02-14 2009-08-26 Bayer Pharmaceuticals Corp Formulierungsstrategien zur stabilisierung von peptiden in organischen lösungsmitteln und in getrockneten zuständen
WO2004062684A2 (en) * 2003-01-16 2004-07-29 D. Collen Research Foundation Vzw Onderwijs En Navorsing Campus Gasthuisberg K.U. Leuven Treatment of thrombocytopenia with inhibitors of pacap
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
ES2725808T3 (es) 2003-05-23 2019-09-27 Nektar Therapeutics Derivados de PEG que contienen dos cadenas de PEG
RU2006130691A (ru) * 2004-01-27 2008-03-10 Байер Фармасьютикалс Корпорейшн (US) Агонисты рецептора (vpac2), активирующего аденилатциклазу гипофиза пептида (расар), и фармакологические способы их применения
EP1756156B1 (de) * 2004-05-21 2008-10-22 Eli Lilly And Company Selektive peptidische agonisten des vpac2-rezeptors
EP1753780B1 (de) * 2004-05-21 2008-03-19 Eli Lilly And Company Selektive peptidische agonisten des vpac2-rezeptors
EP1768686A4 (de) * 2004-06-12 2007-11-14 Bayer Pharmaceuticals Corp Pegylierung von vasoaktivem intestinalem peptid (vip)/hypophysen-adenylat-cyclase-aktivierendem peptid (pacap) rezeptor 2 (vpac2) agonisten und anwendungsverfahren
EP1781692A2 (de) * 2004-08-18 2007-05-09 Eli Lilly And Company Selektive vpac2-rezeptor-peptidagonisten
EP1804820A4 (de) 2004-10-08 2009-12-02 Transition Therapeutics Inc Vasoaktive intestinale polypeptid-pharmazeutika
US7595294B2 (en) * 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
KR20140030327A (ko) 2005-01-10 2014-03-11 콜텐도 인베스트 아베 당뇨병, 대사 증후군 및 다른 질환을 치료하기 위한 방법 및 조성물
JP2008539723A (ja) * 2005-05-06 2008-11-20 バイエル・フアーマシユーチカルズ・コーポレーシヨン 下垂体アデニル酸シクラーゼ活性化ペプチド（ｐａｃａｐ）受容体（ｖｐａｃ２）アゴニストおよびそれらの薬理学的使用方法
WO2007021498A1 (en) * 2005-08-11 2007-02-22 Eli Lilly And Company Selective vpac2 receptor peptide agonists
EP1942941A1 (de) 2005-10-26 2008-07-16 Eli Lilly And Company Selektive peptidische agonisten des vpac2-rezeptors
EP1801098A1 (de) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylharnstoff Derivative als selektive 11B-HSD1 Inhibitoren
TW200745163A (en) * 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
RU2009116632A (ru) 2006-10-02 2010-11-10 Кортендо Инвест, Аб (Se) Энантиомер кетоконазола у людей
EP1935420A1 (de) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-Butyramid Derivate als selektive 11Beta-HSD1 Inhibitoren
EP2110374A1 (de) 2008-04-18 2009-10-21 Merck Sante Benzofuran, Benzothiophen, Benzothiazolderivate als FXR-Modulatoren
KR20110022089A (ko) 2008-06-27 2011-03-04 노파르티스 아게 유기 화합물
WO2010056717A1 (en) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
WO2010112520A1 (en) 2009-04-01 2010-10-07 Novartis Ag Spiro derivatives for the modulation of stearoyl-coa desaturase
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011508A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
JP2013506638A (ja) 2009-10-01 2013-02-28 ノバルティス アーゲー ステアロイル−ＣｏＡデサチュラーゼを調節するピラゾール誘導体
EP2501685A1 (de) 2009-11-16 2012-09-26 Mellitech [1,5]-diazocin-derivate
CN103664873B (zh) 2009-12-30 2016-06-15 深圳信立泰药业股份有限公司 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
CU24075B1 (es) * 2011-08-26 2015-01-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.
CN104411710A (zh) 2012-04-16 2015-03-11 卡内克制药公司 作为ptp-1b抑制剂前体的稠合的芳族膦酸酯衍生物
EP3035950A4 (de) * 2013-08-14 2017-05-03 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glykosylierte pacap/vip-analoga mit verbesserter penetration zur behandlung neurodegenerativer erkrankungen
AU2015247921B2 (en) 2014-04-17 2019-07-11 Merck Sharp & Dohme Llc Sitagliptin tannate complex
CA2982861A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
SG10202109689QA (en) 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Humanized anti-pacap antibodies and uses thereof
EP3863634A1 (de) 2018-10-12 2021-08-18 Strongbridge Dublin Limited Levoketoconazol zur behandlung von kongenitaler adrenalhyperplasie und primärem aldosteronismus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3107225B2 (ja) * 1990-03-17 2000-11-06 武田薬品工業株式会社 Ｐａｃａｐに対する抗体およびその用途
AU656230B2 (en) * 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
AU682638B2 (en) * 1995-06-09 1997-10-09 ILS, Inc. Peptide, bronchodilator and blood flow ameliorant
WO1998002453A2 (en) * 1996-07-15 1998-01-22 Universite Libre De Bruxelles Peptidic ligands having a higher selectivity for the vip1 receptor than for the vip2 receptor
FR2775902B1 (fr) * 1998-03-13 2001-05-11 Assist Publ Hopitaux De Paris Utilisation d'analogues du vip dans la prevention et le traitement des lesions cerebrales du nouveau-ne humain
WO2000005260A1 (en) * 1998-07-20 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Peptide analogues of pacap

Also Published As

Publication number Publication date
CZ296858B6 (cs) 2006-07-12
AU7726600A (en) 2001-04-30
EP1192182B1 (de) 2008-06-04
SV2002000184A (es) 2002-06-07
MY131983A (en) 2007-09-28
HUP0202175A3 (en) 2005-01-28
GT200000162A (es) 2002-03-22
CZ20021085A3 (cs) 2003-01-15
DOP2000000071A (es) 2002-02-28
PE20010612A1 (es) 2001-07-12
RU2269354C2 (ru) 2006-02-10
HUP0202175A2 (en) 2002-10-28
TWI264438B (en) 2006-10-21
DE60039111D1 (de) 2008-07-17
WO2001023420A2 (en) 2001-04-05
SK5552002A3 (en) 2003-05-02
CO5280048A1 (es) 2003-05-30
WO2001023420A3 (en) 2001-08-30
ES2307534T3 (es) 2008-12-01
CA2379604A1 (en) 2001-04-05
EP1192182A2 (de) 2002-04-03
UY26360A1 (es) 2001-04-30

Similar Documents

Publication Publication Date Title
ATE397625T1 (de) Agonisten des rezeptors 3 (r3) von pituitary adenylate cyclase aktivierendem peptid (pacap) und ihre pharmakologische verwendung
RU2001136014A (ru) Агонисты рецептора-3 (r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения
DOP2003000669A (es) Agonistas del receptor (vpac2) del peptido activante de la adelinato ciclasa hipofisaria (pacap) y sus metodos de uso farmacológicos
DK0699686T3 (da) Biologisk aktive fragmenter af glukagon-lignende insulinotropisk peptid
CN104144704B (zh) Glp‑1受体激动剂肽胃泌素缀合物
KR20120062777A (ko) 변형된 혈관활성 장 펩티드
AU657723B2 (en) Nonapeptide bombesin antagonists
CN114222755B (zh) Glp-1和gip受体双重激动剂化合物及其应用
EP0438519A4 (en) Therapeutic peptides
HK1080363B (zh) 具有血管活性腸肽的生物學活性的化合物在治療結節病中的用途
Lin et al. Comparison of the peptide structural requirements for high affinity interaction with bombesin receptors
WO2005072385A3 (en) Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
CA2205663A1 (en) Neuromedin b receptor antagonists
Fahrenkrug et al. Characterization and regional distribution of peptides derived from the vasoactive intestinal peptide precursor in the normal human brain
JP2002522355A (ja) 新規な混合アミリン活性化合物
CN112608378B (zh) 一类glp-1/胆囊收缩素-1受体双重激动剂及其应用
Dietrich et al. Effects of BIM26226, a potent and specific bombesin receptor antagonist, on amylase release and binding of bombesin-like peptides to AR4-2J cells
Suzuki et al. Comparison of the insulinotropic activity of glucagon-superfamily peptides in rat pancreas perfusion
ECSP003683A (es) Agonistas del receptor 3(r3) del peptido activador de la adenilato ciclasa de la pituitaria y sus metodos de uso farmacologico
AR025902A1 (es) Agonistas del receptor 3 (r3) del peptido activador de la adenilato ciclasa de la pituitaria y sus metodos de uso farmacologico
Rossier GRF update: is this the last hypothalamic hypophysiotropic factor?
Duntas et al. Atrial natriuretic peptide-like immunoreactive material (ANP-LI) is released from the adrenal gland by splanchnic nerve stimulation
Rivier et al. Conformationally altered fragments of rat GRF: VIP homologs, analogs or both?
Vaysse Somatostatin 14 and 28: Modulation of the action of VIP and related peptides
Solcia et al. Immunocytochemical detection of peptides of the glucagon-secretin-VIP-GIP family in endocrine cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties